Workflow
Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - Tenaya Therapeutics has had a strong start to the year and is on track to meet its guidance for the year [2] - The company successfully dosed the high-dose cohort in its 201 lead gene therapy program for the leading genetic cause of hypertrophic cardiomyopathy (HCM) and received DSMB clearance, indicating safety [2] - Tenaya Therapeutics has released data from the largest natural history study for children with a specific mutation related to this severe disease [2] - The company is expected to deliver additional data in the second half of the year, with a narrowed guidance to Q4 [3]